Deep Vein Thrombosis News and Research

RSS

Deep vein thrombosis, or DVT, is a blood clot that forms in a vein deep in the body. Most deep vein clots occur in the lower leg or thigh. If the vein swells, the condition is called thrombophlebitis. A deep vein thrombosis can break loose and cause a serious problem in the lung, called a pulmonary embolism, or a heart attack or stroke.

Detecting dangerous blood clots in the form of simple urine test

Detecting dangerous blood clots, which can cause life-threatening conditions such as strokes and heart attacks, leading causes of death for men and women in the U.S., has been a coveted and elusive goal.

17 Oct 2013

Scientists introduce new approach to the production of synthetic heparin mimetics

One of the risks of any large operation is the occurrence of blood clots. To prevent this, patients are routinely given the anticoagulant heparin or related drugs. American scientists have now introduced a new approach to the production of synthetic heparin mimetics with better activity profiles.

11 Oct 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Choosing Wisely List released by The American Academy of Orthopaedic Surgeons

The American Academy of Orthopaedic Surgeons (AAOS) today released a list of specific tests or procedures that are commonly ordered but not always necessary in orthopaedics as part of the Choosing Wisely- campaign, an initiative of the ABIM Foundation. The list identifies five targeted, evidence-based recommendations that can support conversations between patients and physicians about what care is really necessary.

12 Sep 2013

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.

5 Sep 2013

August edition of NPS RADAR includes reviews for new medicines listed on PBS

The 10th anniversary edition of NPS RADAR contains reviews for new medicines listed on the Pharmaceutical Benefits Scheme including rivaroxaban (Xarelto), rotigotine patches (Neupro) and mifepristone (Mifepristone Linepharma) followed by misoprostol (GyMiso).

1 Aug 2013

ACC report helps clinicians optimize appropriate use of noninvasive vascular tests

A new report issued today by the American College of Cardiology (ACC) and developed in collaboration with 10 other leading professional societies provides detailed criteria to help clinicians optimize the appropriate use of certain noninvasive vascular tests when caring for patients with known or suspected disorders of the venous (veins) system.

20 Jul 2013

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.

11 Jul 2013

Orlando Health's clinicians provide hospital-level care in patient's home

Instead of admitting patients to medical units at the hospital, clinicians at Orlando Regional Medical Center are providing health care to patients in the comfort of their homes. The new twist on modern medicine is being piloted in a project to provide hospital-level care in a patient's home through home visits, videoconferencing (virtual visit) and telemonitoring (remote vital signs monitoring).

28 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

CLOTS 3 trial demonstrates efficacy of Covidien's Kendall SCD system on immobile stroke patients

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien's Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients.

20 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Peripherally inserted central catheters increase risk of dangerous blood clots

Touted for safety, ease and patient convenience, peripherally inserted central catheters have become many clinicians' go-to for IV delivery of antibiotics, nutrition, chemotherapy, and other medications.

20 May 2013

Gene offers new insights into treatment strategies for deep-vein thrombosis

A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis -- the formation of a harmful clot in a deep vein.

9 May 2013

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.

25 Apr 2013

Study: Using best-practice approach could lead to big cost reductions in hospitals nationwide

A major challenge facing today's health care community is to find ways to lower costs without compromising clinical quality. Taking that challenge to task, researchers at Medstar Health and Georgetown University School of Medicine, Washington DC, report success in using a concept called "value-based analysis," which simultaneously measures quality and cost and addresses inefficiencies in care.

11 Apr 2013

Orthopaedic surgeons should recommend weight loss to patients prior to joint replacement

The obesity epidemic in America and its impact on musculoskeletal health, as well as related treatment outcomes and costs, was discussed during the AAOS Now forum, "Obesity, Orthopaedics and Outcomes," at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons at McCormick Place in Chicago.

11 Apr 2013

Women experiencing still birth are more likely to develop blood clots, says study

Women who have suffered a still birth or have medical conditions including varicose veins, inflammatory bowel disease (IBD) or heart disease are at greater risk of developing dangerous blood clots after giving birth, a study has revealed.

3 Apr 2013

Pregnancy-related events increase women's risk of deadly blood clot: Study

Newly identified pregnancy-related events, such as stillbirth or pre-term birth, may dramatically increase a woman's risk of developing a potentially deadly blood clot immediately after pregnancy, according to the results of a large, population-based study published online today in Blood, the Journal of the American Society of Hematology.